Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes

Abstract

Get full access to this article

View all access options for this article.

References

1. Daneshgaran

, Shauly

, Gould

. “Ozempic Face” in plastic surgery: A systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthet Surg J Open Forum. 2025;7:ojaf056.

2. Carboni

, Woessner

, Martini

, et al. Natural weight loss or “Ozempic Face”: Demystifying a social media phenomenon. J Drugs Dermatol. 2024;23(1):1367–1368.

3. Mansour

, Hannawa

, Yaldo

, et al. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225–227.

4. Haykal

, Hersant

, Cartier

, et al. The role of GLP-1 agonists in esthetic medicine: Exploring the impact of semaglutide on body contouring and skin health. J Cosmet Dermatol. 2025;24(2):e16716.

5. Humphrey

, Lawrence

. Implications of ozempic and other semaglutide medications for facial plastic surgeons. Facial Plast Surg. 2023;39(6):719–721.

6. Whitley

, Trujillo

, Neumiller

. Special report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467–473.